Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation Of Non-Human Primate Data For ORX142 At Sleep Europe 2024

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held September 24-27, 2024, in Seville, Spain.

 

The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model.